nach oben

Erschienen in:

01.07.2021 | News item

AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Health Canada is advising healthcare professionals that very rare cases of life-threatening capillary leak syndrome (CLS) have been reported after vaccination with AstraZeneca COVID-19 Vaccine [AZD-1222; ChAdOx1-S], including the AstraZeneca vaccine manufactured by the Serum Institute of India [COVISHIELD]. Use of these vaccines is now contraindicated in people with a previous history of CLS. …

Health Canada. AstraZeneca COVID-19 Vaccine and COVISHIELD: Risk of Capillary Leak Syndrome Internet Document : 29 Jun 2021. Available from: URL: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2021/75947a-eng.php

Titel: AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome
Publikationsdatum: 01.07.2021
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-98931-6

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

AstraZeneca COVID-19 Vaccine-related risk of capillary leak syndrome

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Fexofenadine/pseudoephedrine

Ciclosporin/dexamethasone/methylprednisolone

Atezolizumab/bevacizumab

Opioid-analgesics

Multiple drugs

AZD-1222/dabigatran-etexilate